SAN MATEO, Calif. and SINGAPORE, April 19, 2024 (GLOBE NEWSWIRE) — ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it received a letter (the “Letter”) on April 18, 2024 from The Nasdaq Stock Market (“Nasdaq”) informing the Company that it failed to maintain the continued listing requirement under Nasdaq Listing Rule 5550(b)(1) for the Nasdaq Capital Market, which requires that a listed company’s stockholders’ equity be at least $2.5 million (the “Stockholders’ Equity Requirement”).
GlobeNewswire,is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Latest posts by GlobeNewswire (see all)
- Amazon Technical Interview Preparation Course 2025 – Interview Questions With Amazon Leadership Principles And Amazon Mock Interviews Updated - April 21, 2025
- Good Game Group Unveils $GDGM Token Within TheBlock. Ecosystem to Enhance Gamified Content and Exclusive Membership Perks - April 21, 2025
- CampervanHire.Com Helps Travelers Find RV Rentals With Dynamic Online Search Tools - April 21, 2025
